Avecho Biotechnology 대차 대조표 상태

재무 상태 기준 확인 6/6

Avecho Biotechnology has a total shareholder equity of A$4.2M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$5.9M and A$1.6M respectively.

주요 정보

부채 비율

AU$0

부채

이자 보상 비율	n/a
현금	AU$4.84m
주식	AU$4.22m
총 부채	AU$1.65m
총 자산	AU$5.86m

최근 재무 상태 업데이트

업데이트 없음

Recent updates

재무 상태 분석

단기부채: AVE's short term assets (A$5.6M) exceed its short term liabilities (A$1.6M).

장기 부채: AVE's short term assets (A$5.6M) exceed its long term liabilities (A$58.8K).

부채 대 자본 내역 및 분석

부채 수준: AVE is debt free.

부채 감소: AVE has not had any debt for past 5 years.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: AVE has sufficient cash runway for more than a year based on its current free cash flow.

예측 현금 활주로: AVE has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 15.4% each year.

Avecho Biotechnology 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

Recent updates

First half 2024 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in 1H 2023)

Avecho Biotechnology Limited, Annual General Meeting, May 30, 2024

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2022)

New major risk - Shareholder dilution

Avecho Biotechnology Limited has completed a Follow-on Equity Offering in the amount of AUD 6.04685 million.

First half 2023 earnings released: AU$0.001 loss per share (vs AU$0 in 1H 2022)

Full year 2022 earnings released: AU$0.001 loss per share (vs AU$0.002 loss in FY 2021)

Athenex Submits Avecho's Phytonadione to FDA Pre-IND

Avecho Biotechnology Limited Receives Ethics Approval for its Pivotal Phase III Clinical Trial Testing its Oral CBD Softgel Capsule for Insomnia

Less than half of directors are independent

Avecho Biotechnology Limited Announces Interim Results from Comparative Pharmacokinetic Studies Conducted in the Uk

First half 2022 earnings released: EPS: AU$0 (vs AU$0.001 loss in 1H 2021)

Less than half of directors are independent

Avecho Biotechnology Limited Announces Positive Results for Its Phase IIa Study

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Avecho Biotechnology Limited Announces Dosing Commencement for CBD Topical Osteoarthritis Study in collaboration with the Lambert Initiative

Avecho Biotechnology Limited Releases Results for Its Australian Phase I PK Study Characterizing the Absorption Profile of Cannabidiol from Avecho's Proprietary CBD Soft-Gel Product

Avecho Commences Enrolment for Phase I Human Clinical Trial Measuring CBD Absorption

Non-Independent Non-Executive Director David Segal has left the company

Avecho Biotechnology Limited Completes Pharmaceutical CBD Soft-Gel Product

Full year 2020 earnings released: AU$0.002 loss per share (vs AU$0.001 profit in FY 2019)

Full year 2020 earnings released: AU$0.002 loss per share (vs AU$0.001 profit in FY 2019)

Avecho Biotechnology Begins Human Trial on CBD Product

Avecho Biotechnology Limited Provides TPM Cannabinoid Development Program Update

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기